Articles From: ARC Resources Ltd. announces sixth consecutive year of 200 per cent or greater produced reserves replacement in 2013 to Arcapita Goes After Two Arab Banks to Recover $45.3 Million


2014/3/17
ARC Resources Ltd.
Sign-up for ARC Resources Ltd. Confirms April 15, 2014 Dividend Amount investment picks
ARC Resources Ltd.
Sign-up for ARC Resources Ltd. confirms December 16, 2013 dividend amount investment picks
2014/1/16
ARC Resources Ltd.
Sign-up for ARC Resources Ltd. confirms February 18, 2014 dividend amount investment picks
2013/12/16
ARC Resources Ltd.
Sign-up for ARC Resources Ltd. confirms January 15, 2014 dividend amount investment picks
2014/2/18
ARC Resources Ltd.
Sign-up for ARC Resources Ltd. confirms March 17, 2014 dividend amount investment picks
ARC Resources Ltd.
Sign-up for ARC Resources Ltd. Confirms November 15, 2013 Dividend Amount investment picks
ARC Resources Ltd.
Sign-up for ARC Resources Ltd. Confirms October 15, 2013 Dividend Amount investment picks
ARC Resources Ltd.
Sign-up for ARC Resources Ltd. Confirms September 16, 2013 Dividend Amount investment picks
ARC Resources Ltd.
Sign-up for ARC Resources Ltd. promotes Mr. Terry M. Anderson to Chief Operating Officer investment picks
2014/2/5
ARC Resources Ltd.
Sign-up for ARC Resources Ltd. reports fourth quarter and year end 2013 results investment picks
2013/11/6
ARC Resources Ltd.
Sign-up for ARC Resources Ltd. reports third quarter 2013 results investment picks
2013/11/6
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, and Duke University’s Duke Clinical Research Institute (DCRI), the world’s largest academic clinical research organization (ARO), today announced a new agreement under which ARCA and the DCRI will work together to execute GENETIC-AF, a planned Phase 2B/3 genetically-targeted, comparative effectiveness clinical trial evaluating Gencaro™ (bucindolol hydrochloride) as a potential treatment for the prevention of atrial fibrillation (AF) in patients with heart failure.
Sign-up for ARCA biopharma Announces Clinical Trial Agreement for GENETIC-AF Trial investment picks
2013/12/5
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Laboratory Corporation of America (LabCorp®) (NYSE: LH) has informed ARCA that LabCorp has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for the planned companion diagnostic test for Gencaro TM (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation (AF). If accepted by the FDA, the IDE will allow the companion diagnostic test to be used in the planned GENETIC-AF clinical trial.
Sign-up for ARCA biopharma Announces IDE Submission to US FDA for Gencaro Companion Diagnostic Test investment picks
2013/10/29
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the GENETIC-AF clinical trial of Gencaro (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation (AF). ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted AF prevention treatment.
Sign-up for ARCA biopharma Announces IND Submission to US FDA for Gencaro for the Treatment of Atrial Fibrillation investment picks
2014/2/4
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has priced its previously announced public offering of common stock and warrants at a price of $1.70 for each share of common stock and a related warrant to purchase 0.25 shares of common stock, for gross proceeds of $8.7 million, prior to deducting underwriting discounts and commissions and offering expenses of the Company.
Sign-up for ARCA biopharma Announces Pricing of $9 Million Public Offering of Common Stock and Warrants investment picks
2014/2/3
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it intends to offer and sell common stock and warrants in a public offering.
Sign-up for ARCA biopharma Announces Proposed Public Offering of Common Stock and Warrants investment picks
2013/11/21
ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that John L.
Sign-up for ARCA biopharma Announces Resignation from Board of Directors investment picks
2014/1/8
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Laboratory Corporation of America (LabCorp®) (NYSE: LH) has informed ARCA that the U.S. Food and Drug Administration (FDA) has accepted LabCorp’s Investigational Device Exemption (IDE) application for the planned companion diagnostic test for Gencaro TM (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation (AF). The IDE allows the companion diagnostic test to be used in the planned GENETIC-AF clinical trial.
Sign-up for ARCA biopharma Announces US FDA Acceptance of Gencaro Companion Diagnostic Test IDE investment picks
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the Company’s Gencaro TM Investigational New Drug (IND) application for atrial fibrillation (AF) has been accepted by the U.S. Food and Drug Administration (FDA) and is now active.
Sign-up for ARCA biopharma Announces US FDA Acceptance of Gencaro IND Application for the Treatment of Atrial Fibrillation investment picks
2014/3/19
http://media.marketwire.com/attachments/201403/TN-233143_Michael-Bristow-muncmedia-1800publicrelations-pr-ny-agencyphoto.jpg CEO MICHAEL BRISTOW of ARCA Biopharma, Inc. (NASDAQ: ABIO) - Clear Channel Business Talk Radio 'The Traders Network Show' broadcasted live daily M-F from 1pm-3pm CT.
Sign-up for ARCA biopharma CEO Michael R. Bristow to Be Interviewed Live Today on Clear Channel Business Talk Radio investment picks
2014/4/4
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow the Company to sell, from time to time, up to $75 million of its common stock, preferred stock, depository shares, debt securities and/or warrants in one or more offerings.
Sign-up for ARCA biopharma Files Shelf Registration Statement investment picks
2014/1/7
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Dr.
Sign-up for ARCA biopharma to Present at Biotech Showcase 2014 investment picks
ARCA biopharma, Inc. (Nasdaq: ABIO) , a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that its President and CEO, Dr.
Sign-up for ARCA biopharma to Present at the Rodman & Renshaw Annual Global Investment Conference investment picks
2013/11/14
- North American Tour Kicks Off On March 6 - - Tickets On Sale Starting November 22 at www.LiveNation.com - LOS ANGELES , Nov.
Sign-up for Arcade Fire REFLEKTOR TOUR 2014 investment picks
2014/3/13
LONDON and ATLANTA, March 13, 2014 (GLOBE NEWSWIRE) -- Global Supply Chain Commerce Solutions provider, Manhattan Associates (Nasdaq:MANH) , today announced that Arcadia Group, the UK based multi-national retailer, has selected multiple components from Manhattan's Supply Chain Commerce Solutions portfolio to enable new supply chain processes and maximize service levels across its growing omni-channel retail operations.
Sign-up for Arcadia Selects Manhattan Supply Chain Commerce Platform to Orchestrate Omni-Channel Fulfilment Operation and Drive Business Growth investment picks
2014/2/24
Arcadyan Enters LTE Carrier Market with Proven and Scalable Solution from Cavium SAN JOSE, Calif.
Sign-up for Arcadyan Selects Cavium for Carrier-grade LTE Small Cells with Data Offload and DPI for Enterprise Applications investment picks
2014/3/18
Arcapita Bank is suing two Arab banks to recover a total of $45.3 million the investment firm transferred to them just before its 2012 bankruptcy filing.
Sign-up for Arcapita Goes After Two Arab Banks investment picks
2014/3/18
By Joseph Checkler Arcapita Bank is suing two Arab banks to recover a total of $45.3 million the investment firm transferred to them just before its 2012 bankruptcy filing.
Sign-up for Arcapita Goes After Two Arab Banks to Recover $45.3 Million investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: ARC Resources Ltd. announces sixth consecutive year of 200 per cent or greater produced reserves replacement in 2013 to Arcapita Goes After Two Arab Banks to Recover $45.3 Million
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity